Report Description

Global ovarian cancer diagnostics market may register an impressive growth in the forecast period, 2023-2027, due to growing demands for the early diagnosis for ovarian cancer. Surge in the instances of ovarian cancer and demands for the early detection such that timely treatments could be provided, is driving the growth of the global ovarian cancer diagnostics market in the upcoming five years. Ovarian cancer is one of the major factors behind rising mortality rates worldwide among female population that is further supporting the growth of the global ovarian cancer diagnostics market in the next five years. Due to various factors like environmental factors and genetic mutations, the instances of cancer in the ovaries and cysts are increasing. Advancing healthcare services and better patient care services further substantiate the growth of the global ovarian cancer diagnostics market in the forecast years.

Cancer is a chronic disease where tumors and cysts are formed in certain organs of organ sites that is abnormal and do not undergo complete cell growth before division and causes lumps at the sites. These cancer lumps hinder with the functioning of the organ as well as the complete human body system thereby worsening the health of the patient. Ovarian cancer is a cancer type that takes place in female population in their egg producing organ, ovaries. Diagnosis of ovarian cancer is difficult since the symptoms are very vague and are often detected only after they have already spread through stomach and within pelvis making it difficult to cure. Thus, better diagnostic processes and techniques are required to identify the cancer stage to treat them in due time.

Growing Disease Burden Benefits Market Growth

Increasing instances of ovarian cancer among the female population are major factor that drives the growth of the global ovarian cancer diagnostics market in the upcoming five years. In the year 2020 there were 313,959 new ovarian cancer cases on a global scale. Further, increasing mortality rate due to ovarian cancer is alarming and it further portrays the importance of the early diagnosis of the ovarian cancer such that treatment could be provided. Total number of deaths caused due to ovarian cancer globally in the year 2020 was 207,252.

The American Cancer Society estimates that in 2022, about 19,880 new cases of ovarian cancer will be diagnosed and 12,810 women will die of ovarian cancer in the United States by the end of 2022. Such alarming figures have increased concerns among the population not only in the country but globally. Rising awareness regarding threat of ovarian cancer and its caused high mortality rates also substantiates the growth of the global ovarian cancer diagnostics market in the future five years.


Click here to download the sample

Market Segmentation

The global ovarian cancer diagnostics market segmentation is based on diagnosis type, cancer type, end user, regional distribution, and competitive landscape. Based on diagnosis type, the market is further segmented into diagnostic imaging, blood test, biopsy, and others. Diagnostic imaging includes transvaginal ultrasound, CT scan, MRI scan, pet scan, and others. Blood tests include CA-125, HER2, BRCA, KRAS mutation, and others. Biopsy includes image guided biopsy, fine needle aspiration biopsy, and others. By cancer type, the market is fragmented into epithelial tumor, germ cell tumor, stromal cell tumor, and others. Based on end user, the market is bifurcated into hospitals & specialty clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics, Inc., Siemens Healthineers AG, Thermo Fischer Scientific, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), MiRXES Pte Ltd, GinaLife, Luminex Corporation, Myriad Genetics Inc., are enlisted in a partial list of major market players of the global ovarian cancer diagnostics market.

Attribute

Details

Base Year

2021

Historical Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

  • Diagnosis Type
  • Cancer Type
  • End User

Regional scope

North America; Europe & CIS; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, Brazil, Argentina, Colombia, South Africa, UAE, Saudi Arabia.

Key companies profiled

Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics, Inc., Siemens Healthineers AG, Thermo Fischer Scientific, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), MiRXES Pte Ltd, GinaLife, Luminex Corporation, Myriad Genetics Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global ovarian cancer diagnostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Ovarian Cancer Diagnostics Market, By Diagnosis Type:
    • Diagnostic Imaging
      • Transvaginal Ultrasound
      • CT Scan
      • MRI Scan
      • PET Scan
      • Others
    • Blood Test
      • CA-125
      • HER2
      • BRCA
      • KRAS Mutation
      • Others
    • Biopsy
      • Image Guided Biopsy
      • Fine Needle Aspiration Biopsy
      • Others
    • Others
  • Ovarian Cancer Diagnostics Market, By Cancer Type:
    • Epithelial Tumor
    • Germ Cell Tumor
    • Stromal Cell Tumor
    • Others
  • Ovarian Cancer Diagnostics Market, By End User:
    • Hospitals & Specialty Clinics
    • Ambulatory Care Centers
    • Others
  • Ovarian Cancer Diagnostics Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Europe
      • France
      • Germany
      • United Kingdom
      • Spain
      • Italy
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer diagnostics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Ovarian Cancer Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Type Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Ovarian Cancer Diagnostics Market

4.    Voice of Customer

5.    Executive Summary

6.    Global Ovarian Cancer Diagnostics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

6.2.1.1.         By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

6.2.1.2.         By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

6.2.1.3.         By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

6.2.2.     By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

6.2.3.     By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

6.2.4.     By Company (2021)

6.2.5.     By Region

6.3.  Product Market Map

7.    North America Ovarian Cancer Diagnostics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

7.2.1.1.         By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

7.2.1.2.         By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

7.2.1.3.         By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

7.2.2.     By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

7.2.3.     By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

7.2.4.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Ovarian Cancer Diagnostics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Diagnosis Type

7.3.1.2.2.             By Cancer Type

7.3.1.2.3.             By End User

7.3.2.     Mexico Ovarian Cancer Diagnostics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Diagnosis Type

7.3.2.2.2.             By Cancer Type

7.3.2.2.3.             By End User

7.3.3.     Canada Ovarian Cancer Diagnostics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Diagnosis Type

7.3.3.2.2.             By Cancer Type

7.3.3.2.3.             By End User

8.    Europe Ovarian Cancer Diagnostics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

8.2.1.1.         By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

8.2.1.2.         By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

8.2.1.3.         By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

8.2.2.     By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

8.2.3.     By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Ovarian Cancer Diagnostics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Diagnosis Type

8.3.1.2.2.             By Cancer Type

8.3.1.2.3.             By End User

8.3.2.     Germany Ovarian Cancer Diagnostics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Diagnosis Type

8.3.2.2.2.             By Cancer Type

8.3.2.2.3.             By End User

8.3.3.     United Kingdom Ovarian Cancer Diagnostics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Diagnosis Type

8.3.3.2.2.             By Cancer Type

8.3.3.2.3.             By End User

8.3.4.     Italy Ovarian Cancer Diagnostics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Diagnosis Type

8.3.4.2.2.             By Cancer Type

8.3.4.2.3.             By End User

8.3.5.     Spain Ovarian Cancer Diagnostics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Diagnosis Type

8.3.5.2.2.             By Cancer Type

8.3.5.2.3.             By End User

9.    Asia-Pacific Ovarian Cancer Diagnostics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

9.2.1.1.         By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

9.2.1.2.         By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

9.2.1.3.         By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

9.2.2.     By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

9.2.3.     By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

9.2.4.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Ovarian Cancer Diagnostics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Diagnosis Type

9.3.1.2.2.             By Cancer Type

9.3.1.2.3.             By End User

9.3.2.     India Ovarian Cancer Diagnostics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Diagnosis Type

9.3.2.2.2.             By Cancer Type

9.3.2.2.3.             By End User

9.3.3.     Japan Ovarian Cancer Diagnostics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Diagnosis Type

9.3.3.2.2.             By Cancer Type

9.3.3.2.3.             By End User

9.3.4.     South Korea Ovarian Cancer Diagnostics Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Diagnosis Type

9.3.4.2.2.             By Cancer Type

9.3.4.2.3.             By End User

9.3.5.     Australia Ovarian Cancer Diagnostics Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Diagnosis Type

9.3.5.2.2.             By Cancer Type

9.3.5.2.3.             By End User

10.  South America Ovarian Cancer Diagnostics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

10.2.1.1.      By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

10.2.1.2.      By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

10.2.1.3.      By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

10.2.2.  By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

10.2.3.  By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

10.2.4.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Ovarian Cancer Diagnostics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Diagnosis Type

10.3.1.2.2.           By Cancer Type

10.3.1.2.3.           By End User

10.3.2.  Argentina Ovarian Cancer Diagnostics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Diagnosis Type

10.3.2.2.2.           By Cancer Type

10.3.2.2.3.           By End User

10.3.3.  Colombia Ovarian Cancer Diagnostics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Diagnosis Type

10.3.3.2.2.           By Cancer Type

10.3.3.2.3.           By End User

11.  Middle East and Africa Ovarian Cancer Diagnostics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Diagnosis Type (Diagnostic Imaging, Blood Test, Biopsy, Others)

11.2.1.1.      By Diagnostic Imaging (Transvaginal Ultrasound, CT Scan, MRI Scan, PET Scan, Others)

11.2.1.2.      By Blood Test (CA-125, HER2, BRCA, KRAS Mutation, Others)

11.2.1.3.      By Biopsy (Image Guided Biopsy, Fine Needle Aspiration Biopsy, Others)

11.2.2.  By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Others)

11.2.3.  By End User (Hospitals & Specialty Clinics, Ambulatory Care Centers, Others)

11.2.4.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Ovarian Cancer Diagnostics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Diagnosis Type

11.3.1.2.2.           By Cancer Type

11.3.1.2.3.           By End User

11.3.2.  Saudi Arabia Ovarian Cancer Diagnostics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Diagnosis Type

11.3.2.2.2.           By Cancer Type

11.3.2.2.3.           By End User

11.3.3.  UAE Ovarian Cancer Diagnostics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Diagnosis Type

11.3.3.2.2.           By Cancer Type

11.3.3.2.3.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Abbott Laboratories, Inc.

14.2.              Bio-Rad Laboratories, Inc.

14.3.              Quest Diagnostics, Inc.

14.4.              Siemens Healthineers AG

14.5.              Thermo Fischer Scientific, Inc.

14.6.              F. Hoffmann-La Roche Ltd (Foundation Medicine)

14.7.              MiRXES Pte Ltd

14.8.              GinaLife

14.9.              Luminex Corporation

14.10.            Myriad Genetics Inc.

15.  Strategic Recommendations

(Note: The companies list can be customized based on the client requirements.)

Figures and Tables

Frequently asked questions

down-arrow

Global ovarian cancer diagnostics market may grow with impressive CAGR during the forecast period, 2023-2027, on account of growing mortality rate due to ovarian cancer.

down-arrow

The global ovarian cancer diagnostics market is segmented into North America region, South America region, Asia Pacific region, European region, and Middle East & Africa region for the regional analysis of the market. North America region is anticipated to dominate the market analysis in the upcoming five years on the account of growing healthcare industry.

down-arrow

Abbott Laboratories, Inc., Bio-Rad Laboratories, Inc., Quest Diagnostics, Inc., Siemens Healthineers AG, Thermo Fischer Scientific, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), MiRXES Pte Ltd, GinaLife, Luminex Corporation, Myriad Genetics Inc., among others are some of the leading companies dedicated toward providing related products and services of ovarian cancer diagnostics and support the future growth of the global ovarian cancer diagnostics market in the upcoming five years.

down-arrow

New market players may invest actively in research and innovative product development. Also, advancing their existent technology according to evolving consumer preferences along with merger and acquisitions with the global giants can be viable strategic recommendations for the future brand establishments.

profile

Sakshi Bajaal

Business Consultant
Press Release

Ovarian Cancer Diagnostics Market Growing with Advanced Technology Developments

May, 2022

Global Ovarian Cancer Diagnostics Market is anticipated to grow with increasing instances of ovarian cancer in female population.